Objective:

To investigate factors influencing progression-free survival (PFS) and overall survival (OS) in pediatric meningiomas (PMs) and inform clinical practice guidelines, particularly those addressing the unique needs of this population.

Key Findings:

• Mean PFS for ages 0–3, 4–12, and 13–21 were 51.3 months (95% CI: 26.4–76.2), 115.1 months (95% CI: 99.2–130.9), and 158.9 months (95% CI: 121.7–196.1), respectively.
• PFS was significantly shorter for those diagnosed at ages 0–3 compared to older age groups.
• OS showed no significant differences across age groups, with means of 261.7 months (95% CI: 217.8–305.6), 212.3 months (95% CI: 180.1–244.5), and 594.5 months (95% CI: 500.0–689.0).

Interpretation:

Pediatric meningiomas exhibit distinct survival patterns based on age, with younger patients having shorter PFS but similar OS across age groups, indicating a need for age-specific treatment approaches.

Limitations:

• Lack of detailed data on adjuvant chemotherapy limits the analysis of treatment effects.
• The retrospective nature of most included studies may introduce bias, affecting the reliability of the findings.

Conclusion:

This meta-analysis highlights the need for tailored management strategies for pediatric meningiomas, considering their unique clinical characteristics and survival outcomes, such as age-specific treatment protocols.